Business
Allogene Therapeutics Announces Preclinical Publication Highlighting Superiority of Healthy Donor-Derived Allogeneic CAR T Cells Over Patient-Derived Cells in Multiple Myeloma
Results Demonstrated Anti-BCMA CAR T Cells Derived from Healthy Donors Had Better Immune Fitness and Killing ActivityPhase 1 AlloCAR T™ Trials Underway
About this update from Allogene Therapeutics, Inc.
[{"type":"text","content":"Results Demonstrated Anti-BCMA CAR T Cells Derived from Healthy Donors Had Better Immune Fitness and Killing ActivityPhase 1 AlloCAR T™ Trials Underway Evaluating ALLO-715 and ALLO-605 for the Treatment of Relapsed/Refractory Multiple Myeloma BCMA Program Clinical Update Expected by the End of 2022 SOUTH SAN FRANCISCO, Calif., March 23, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced the publication of preclinical study results demonstrating the superior long-term in vitro myeloma-killing activity of allogeneic anti-BCMA CAR T cells from healthy donors compared with anti-BCMA CAR T cells from patients with multiple myeloma. The findings were published in Cancer Research Communications, a journal of the American Association for Cancer Research. “Despite the rapidly evolving treatment landscape for multiple myeloma, this hematologic cancer remains incurable. With so many patients experiencing aggressive disease progression, novel, effective and readily available therapies are needed,” said Reuben Benjamin, MBBS, FRCPath, Ph.D., co-author of the publication and Consultant Hematologist at King’s College Hospital in London. “This preclinical study provides strong evidence of the potential benefits of an allogeneic CAR T therapy derived from young healthy donors over an autologous approach in which a patient’s own T cells are genetically engineered to attack myeloma cancer cells. T cells derived from healthy donors were more abundant, had greater fitness and anti-cancer killing potential, and have the ability to be administered without delay.” BCMA is a validated target in multiple myeloma due to its high specificity and broad expression. In this study led by Ana M. Metelo M.Sc. Ph.D., Postdoctoral Research Associate at King’s College London, anti-BCMA CAR T cells were generated from young healthy donors and from patients with relapsed/refractory multiple myeloma (median age: 61 years) and their profile, fitness and cytotoxic (anti-tumor) activity were compared. Results showed that: Healthy donors had higher T cell counts, a higher CD4/CD8 T cell ratio, and naïve/stem cell memory phenotype compared with patients with relapsed multiple myeloma.Anti-BCMA allogeneic CAR T cells deriv...